High
65.820
Open
65.080
VWAP
--
Vol
7.61M
Mkt Cap
10.73B
Low
61.620
Amount
--
EV/EBITDA(TTM)
--
Total Shares
173.12M
EV
11.75B
EV/OCF(TTM)
--
P/S(TTM)
11.75
Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. The Company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. Its product lines include genomics, data, and artificial intelligence applications (AI). Its genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction (PCR), profiling, molecular genotyping, and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
Show More
8 Analyst Rating
0Wall Street analysts forecast TEM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEM is 68.86 USD with a low forecast of 62.00 USD and a high forecast of 75.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
3 Hold
0 Sell
Moderate Buy
0Current: 62.000
Low
62.00
Averages
68.86
High
75.00
0Current: 62.000
Low
62.00
Averages
68.86
High
75.00
Guggenheim
Buy
maintain
$65 -> $75
2025-06-30
Reason
Guggenheim
Price Target
$65 -> $75
2025-06-30
maintain
Buy
Reason
Guggenheim raised the firm's price target on Tempus AI to $75 from $65 and keeps a Buy rating on the shares. The price target increase reflects new tailwinds in the data business, the analyst tells investors in a research note.
BofA
Neutral
maintain
$68 -> $70
2025-06-25
Reason
BofA
Price Target
$68 -> $70
2025-06-25
maintain
Neutral
Reason
Spruce Point Capital Management
downgrade
2025-05-28
Reason
Spruce Point Capital Management
Price Target
2025-05-28
downgrade
Reason
BofA
Michael Ryskin
Neutral
maintain
$48 -> $68
2025-05-20
Reason
BofA
Michael Ryskin
Price Target
$48 -> $68
2025-05-20
maintain
Neutral
Reason
BofA analyst Michael Ryskin raised the firm's price target on Tempus AI to $68 from $48 and keeps a Neutral rating on the shares based on recent Q1 earnings and a higher multiple due to peer group multiple expansion. The firm cites the stock's premium valuation as well as continuing debate on the true underlying growth rates of the various components of the business for its Neutral rating.
Piper Sandler
Neutral
upgrade
$55 -> $70
2025-05-15
Reason
Piper Sandler
Price Target
$55 -> $70
2025-05-15
upgrade
Neutral
Reason
Piper Sandler raised the firm's price target on Tempus AI to $70 from $55 following quarterly results. The firm keeps a Neutral rating on the shares.
BTIG
Mark Massaro
Strong Buy
Initiates
$60
2025-04-21
Reason
BTIG
Mark Massaro
Price Target
$60
2025-04-21
Initiates
Strong Buy
Reason
BTIG initiated coverage of Tempus AI with a Buy rating and $60 price target.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Tempus AI Inc (TEM.O) is -83.31, compared to its 5-year average forward P/E of -66.27. For a more detailed relative valuation and DCF analysis to assess Tempus AI Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-66.27
Current PE
-83.31
Overvalued PE
-38.16
Undervalued PE
-94.37
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
274.71
Current EV/EBITDA
9005.29
Overvalued EV/EBITDA
2748.98
Undervalued EV/EBITDA
-2199.57
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
8.36
Current PS
8.43
Overvalued PS
10.03
Undervalued PS
6.69
Financials
Annual
Quarterly
FY2025Q1
YoY :
+75.38%
255.74M
Total Revenue
FY2025Q1
YoY :
-25.06%
-40.37M
Operating Profit
FY2025Q1
YoY :
+5.09%
-68.04M
Net Income after Tax
FY2025Q1
YoY :
-28.57%
-0.40
EPS - Diluted
FY2025Q1
YoY :
+1.40%
-109.00M
Free Cash Flow
FY2025Q1
YoY :
+13.91%
60.69
Gross Profit Margin - %
FY2025Q1
YoY :
-47.60%
-26.47
FCF Margin - %
FY2025Q1
YoY :
-40.09%
-26.60
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
60.4M
USD
17
3-6
Months
305.4M
USD
44
6-9
Months
245.6M
USD
28
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
1
17.8M
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 884.13% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
2.8M
Volume
2
6-9
Months
150.0K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
5
1.5M
Volume
Months
6-9
1
150.0K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
1
8.0K
USD
Months
3-6
0
0.0
USD
Months
6-9
1
75.0K
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
60.4M
USD
17
3-6
Months
305.4M
USD
44
6-9
Months
245.6M
USD
28
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
1
17.8M
USD
Months
TEM News & Events
Events Timeline
(ET)
2025-07-16
16:09:52
Moderately bullish activity in tempus AI Inc Class A with shares up 7.31%
2025-07-16
08:03:15
Tempus AI receives FDA clearance for ECG-Low EF software
2025-07-10 (ET)
2025-07-10
13:28:31
Moderately bullish activity in tempus AI Inc Class A with shares up 3.71%
Sign Up For More Events
Sign Up For More Events
News
Preview
3.0
07-28NASDAQ.COMTempus AI or NVIDIA: Which is the Smarter Bet in AI-Backed Healthcare?
Preview
7.0
07-28GlobenewswireBragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vestis and Tempus and Encourages Investors to Contact the Firm
Preview
7.0
07-28PRnewswireTEM Securities Lawsuit Filed Against Tempus AI, Inc. Contact the DJS Law Group to Discuss Your Rights
Sign Up For More News
People Also Watch
THO
Thor Industries Inc
95.180
USD
-0.19%
GATX
GATX Corp
152.470
USD
-0.65%
IBP
Installed Building Products Inc
205.950
USD
+0.72%
UBSI
United Bankshares Inc
36.810
USD
+1.69%
PFSI
PennyMac Financial Services Inc
93.410
USD
-0.70%
PIPR
Piper Sandler Companies
314.260
USD
-0.03%
CYTK
Cytokinetics Inc
36.630
USD
-1.48%
USM
United States Cellular Corp
71.340
USD
-3.52%
BE
Bloom Energy Corp
34.780
USD
+1.28%
VIST
Vista Energy SAB de CV
43.630
USD
-1.96%
FAQ
What is Tempus AI Inc (TEM) stock price today?
The current price of TEM is 62 USD — it has decreased -3.86 % in the last trading day.
What is Tempus AI Inc (TEM)'s business?
What is the price predicton of TEM Stock?
What is Tempus AI Inc (TEM)'s revenue for the last quarter?
What is Tempus AI Inc (TEM)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Tempus AI Inc (TEM)'s fundamentals?
How many employees does Tempus AI Inc (TEM). have?